Hello, everyone, and how are you today? A bright shiny sun and cool breezes are enveloping the Pharmalot campus, a decidedly welcome break from the steamy heat of the past few days. This calls for celebration. So please join us as we reach for the mandatory cup of stimulation. There is another reason to celebrate, by the way, and that is the middle of the week has arrived. In other words, you made it this far, so why not continue? Consider the alternatives, after all. Meanwhile, here are some tidbits. Have a great day, and keep in touch. …

Moderna (MRNA) agreed to provide the U.S. government 100 million doses of its experimental coronavirus vaccine in exchange for more than $1.5 billion, The Wall Street Journal writes. The agreement is the latest with the U.S., which has already secured hundreds of millions of doses from other companies. In this latest deal, the federal government will provide the Moderna vaccine to people in the U.S. free of charge and have the option to purchase up to an additional 400 million doses.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy